الفهرس 
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 239 |  |  |
| | | from | 239 | | |
Abstract
Breast cancer is one of the most common types of
malignant tumors worldwide especially among Egyptian
women’s in Upper Egypt. Recently, Her-2/neu gene status has
become of major clinical significance in breast cancer as a
prognostic and predictive biomarker.
Patients and methods:
This current study was conducted on 67 paraffin
embedded tissue and blood from women with a primary
diagnosis of breast cancer from 2011 to 2013 in Upper Egypt.
Formalin-fixed, paraffin-embedded tissue sections were
analysed for the steroid hormone receptors and Her-2/neu gene
expression using immunohistochemistry (IHC), in addition to
DNA extraction to determine Her-2/neu gene amplification
using quantitative real time PCR technique (RT-PCR). Two
blood samples were collected from each patient, before and
from 3 and 6 months after treatment for RNA extraction to
quantify the gene expression.
Results:
We found 35.82%, 65.67%, 59.7% of the tumour
tissues to be expressed for HER-2/neu protein, ER and PR
using IHC respectively. The expression of Her-2/neu was
correlated significantly with age and negative correlated with each steroid hormone receptors and grade. About 35.82% of
negative immunoreactivity of HER-2/neu was positive
immunoreactivity for both ER and PR and 7.46% of positive
HER-2/neu was negative for both ER and PR. No significant
difference was detected between HER-2/neu amplification by
QRT-PCR and by IHC. All treated groups revealed a decrease
in the level of HER-2/neu mRNA expression on blood
compared to non treated groups except the group treated with
chemotherapy, radiotherapy and hormonal therapy showed an
increase after 3 or 6 months. The highest decrease founded in
the group treated with chemotherapy and radiotherapy.
Conclusion: The expression and amplification of Her-2/neu
gene is biomarker to monitor breast cancer patient’s
responsiveness for Chemo, Radio and Hormonal therapy
treated in Upper Egypt.
Key words: Her-2/neu, immunohistochemistery, real time-
PCR, steroid hormones, mRNA, chemotherapy, radiotherapy,
hormonal therapy.